Research programme: IGF1 receptor monoconal antibodies - Viridian Therapeutics/Zenas BioPharma
Latest Information Update: 12 Mar 2025
At a glance
- Originator Viridian Therapeutics
- Developer Viridian Therapeutics; Zenas BioPharma
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action IGF type 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Graves ophthalmopathy
Most Recent Events
- 05 Feb 2025 Zenas enters into licensing agreement with Zai Lab for Thyroid eye disease in China, Hong Kong, Macau, and Taiwan
- 29 May 2021 Zenas Biopharma plans a clinical trial for Autoimmune in 2022 Zenas Biopharma pipeline, May 2021)
- 23 Mar 2021 Preclinical trials in Graves ophthalmopathy in USA, China (SC) (Zenas Biopharma pipeline, May 2021)